

**In the matter of the Canadian Anti-Doping Program;**

**And in the matter of an anti-doping rule violation by Arshjit Pelia asserted by the Canadian Centre for Ethics in Sport;**

File Outcome Summary

**Summary**

1. The Canadian Centre for Ethics in Sport (CCES) conducted an In-Competition Sample collection session on October 17, 2021, in Toronto, ON.
2. Mr. Arshjit Pelia (“the Athlete”) was selected for Doping Control. The Sample provided by the Athlete returned an Adverse Analytical Finding (“AAF”) for D-Amphetamine, a non-specified Prohibited Substance.
3. Following receipt of the CCES’ Notice of Charge asserting an anti-doping rule violation (“ADRV”) for the presence and Use of the Prohibited Substance, D-Amphetamine, the Athlete waived his right to a hearing, admitted the violation and accepted the proposed period of Ineligibility and all other applicable Consequences by signing an Agreement on Consequences.

**Jurisdiction**

4. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada. The CCES also maintains and implements the Canadian Anti-Doping Program (“CADP”), including providing anti-doping services to national sport organizations and their members.
5. As Canada’s national anti-doping organization, the CCES is in compliance with the World Anti-Doping Code (Code) and its mandatory International Standards. The CCES has implemented the Code and its mandatory International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
6. The Athlete is a member of U SPORTS and participates in the sport of soccer. According to Part C, Rule 1.3 of the CADP, the CADP provisions apply to all members of, and participants in the activities of, sport organizations adopting it. The CADP was adopted by U SPORTS on January 27, 2021. Therefore, as a member of U SPORTS and/or as a participant in U SPORTS sport activities, the Athlete is subject to the Rules of the CADP.

**Doping Control**

7. On October 17, 2021, the CCES conducted an In-Competition Sample collection session in Toronto, ON. Testing was conducted on U SPORTS athletes as part of the CCES’ domestic test distribution plan, all pursuant to the CADP.
8. The Athlete was notified that he had been selected for Doping Control and, together with the doping control officer (DCO) from the CCES, completed the Sample collection process. The Athlete’s Sample code number was 4521118.

9. On October 19, 2021, the Athlete's Sample was received for analysis by the INRS Centre Armand-Frappier Santé Biotechnologie ("INRS"), a World Anti-Doping Agency (WADA) accredited laboratory in Laval, QC.

### **Results Management**

10. The AAF was reported by the INRS on November 8, 2021. The certificate of analysis indicated the presence of D-Amfetamine.
11. D-Amfetamine is classified as a non-specified Prohibited Substance on the 2021 WADA Prohibited List.
12. The CCES commenced an initial review into the Athlete's AAF and issued a notification of a potential ADRV on December 17, 2021
13. On December 17, 2021, in response to the CCES' Notification letter, the Athlete accepted a voluntary Provisional Suspension.
14. On January 4, 2022, the Athlete further communicated to the CCES and indicated they would apply for a retroactive Therapeutic Use Exemption (TUE) in relation to the reported AAF.
15. On March 30, 2022, the Athlete submitted a retroactive-TUE application to the CCES.
16. On September 26, 2022, the Athlete's appeal against the CCES' July 13, 2022, decision denying him a retroactive TUE was dismissed by the Sport Dispute Resolution Centre of Canada (SDRCC).
17. On November 8, 2022, the CCES formally issued a Notice of Charge, asserting an ADRV against the Athlete for the Presence and Use of D-Amfetamine.
18. Having assessed all information provided by the Athlete, the CCES proposed a twenty (20) month period of Ineligibility in accordance with Rules 8.4.1 and 10.2.1.1 and 10.6.2 of the CADP.

### **Confirmation of Violation and Sanction**

19. On November 27, 2022, in accordance with CADP Rule 8.4.1, the Athlete signed an Agreement on Consequences and waived his right to a hearing, thereby admitting the ADRV and accepting both the asserted violation and the proposed period of Ineligibility and all other applicable Consequences.
20. Therefore, the sanction for this violation is a twenty (20) month period of Ineligibility which commenced on December 17, 2021, (the date the Athlete accepted a Provisional Suspension) and concludes on August 16, 2023. Further, in accordance with CADP Rules 10.1 and 10.10, any competitive results obtained by the Athlete during the Event at which his Sample was collected, and from date of Sample collection, must be Disqualified.
21. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 17<sup>th</sup> day of January 2023.



---

Jeremy Luke  
Executive Director, Sport Integrity  
CCES

